The chemical properties of nitric oxide and related nitrogen oxides. In: IgnarroLJ, ed. Nitric Oxide: Biology and Pathobiology. San Diego, CA: Academic Press, 2000; 23–39. , , .
Correlation between nitric oxide formation during degradation of organic nitrates and activation of guanylate cyclase. Eur J Pharmacol 1987; 139: 19–30. , .
Bioactivation of nitroglycerin by the mitochondrial aldehyde dehydrogenase. Trends Cardiovasc Med 2006; 16: 259–65. , .
A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 1986; 46: 6387–92. , .
Enhanced vascular permeability in solid tumor is mediated by nitric oxide and inhibited by both new nitric oxide scavenger and nitric oxide synthase inhibitor. Jpn J Cancer Res 1994; 85: 331–4. , , , .
Modulation of enhanced vascular permeability in tumors by a bradykinin antagonist, a cyclooxygenase inhibitor, and nitric oxide scavenger. Cancer Res 1998; 58: 159–65. , , .
Tumor targeted macromolecular drug delivery based on the enhanced permeability and retention effect in solid tumor. In: LuY, MahatoRI, eds. Pharmaceutical Perspectives of Cancer Therapeutics. New York: AAPS-Springer, 2009; 93–12. , , .
Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS. J Control Release 2001; 74: 47–61. , , .
SMANCS and polymer-conjugated macromolecular drugs: advantages in cancer chemotherapy. Adv Drug Deliv Rev 2001; 46: 169–85. .
Macromolecular therapeutics: advantages and prospects with special emphasis on solid tumour targeting. Clin Pharmacokinet 2003; 42: 1089–105. , , , , .
Augmentation of tumour delivery of macromolecular drugs with reduced bone marrow delivery by elevating blood pressure. Br J Cancer 1993; 67: 975–80. , , , .
Elevating blood pressure as a strategy to increase tumor targeted delivery of macromolecular drug SMANCS: Cases of advanced solid tumors. Jpn J Clin Oncol 2009; doi: 10.1093/jjco/hyp074. , , .
et al. Pegylated zinc protoporphyrin: a water-soluble heme oxygenase inhibitor with tumor-targeting capacity. Bioconjug Chem 2002; 13: 1031–8. , ,
et al. In vivo antitumor activity of pegylated zinc protoporphyrin: targeted inhibition of heme oxygenase in solid tumor. Cancer Res 2003; 63: 3567–74. , ,
Enhancement of chemotherapeutic response of tumor cells by a heme oxygenase inhibitor, pegylated zinc protoporphyrin. Int J Cancer 2004; 109: 1–8. , , , , .
et al. Changes in tumor oxygenation/perfusion induced by the NO donor, isosorbide dinitrate, in comparison with carbogen: monitoring by EPR and MRI. Int J Radiat Oncol Biol Phys 2000; 48 (2): 565–70. , ,
et al. Hypoxic mammalian cell radiosensitization by nitric oxide. Cancer Res 1993; 53 (24): 5845–8. , ,
et al. The acidic tumor microenvironment promotes the reconversion of nitrite into nitric oxide: towards a new and safe radiosensitizing strategy. Clin Cancer Res 2008; 14: 2768–74. , ,
et al. Nitroglycerin treatment may enhance chemosensitivity to docetaxel and carboplatin in patients with lung adenocarcinoma. Clin Cancer Res 2006; 12: 6748–57. , ,
et al. Therapeutic applications of nitric oxide for malignant tumor in animal models and human studies. In: BonavidaB, ed. Nitric Oxide and Cancer. New York: Springer Science, 2009 (in press)., ,